Dyadic International, Inc. (DYAI)

Market Cap	33.31M
Revenue (ttm)	1.80M
Net Income (ttm)	-7.74M
Shares Out	29.48M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,365
Open	1.150
Previous Close	1.140
Day's Range	1.100 - 1.156
52-Week Range	0.930 - 2.670
Beta	0.73
Analysts	Strong Buy
Price Target	6.00 (+430.97%)
Earnings Date	Nov 6, 2024

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein p...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: DYAI
• Website: https://www.dyadic.com

Financial Performance

In 2023, Dyadic International's revenue was $2.90 million, a decrease of -1.07% compared to the previous year's $2.93 million. Losses were -$6.80 million, -30.20% less than in 2022.

Analyst Forecast

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(430.97% upside)

Analyst Consensus: Strong Buy